Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia

British Journal of Haematology

Volumn 144, Issue 2, 2009, Pages 217-222

  Pratt, Guy ^a,b   Harding, Stephen ^c   Holder, Roger ^a   Fegan, Chris ^d   Pepper, Chris ^d   Oscier, David ^e   Gardiner, Anne ^e   Bradwell, Arthur R ^a   Mead, Graham ^a,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c Binding Site Group Ltd   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

Chronic lymphocytic leukaemia; Prognosis; Serum free light chains

Indexed keywords

ALEMTUZUMAB; CD38 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; IMMUNOGLOBULIN LIGHT CHAIN; PREDNISOLONE; PROTEIN KINASE ZAP 70; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BETA 2-MICROGLOBULIN; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOGLOBULIN VARIABLE REGION; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 58149096072     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07456.x     Document Type: Article

References (26)

1. Bradwell, A.R., Carr-Smith, H.D., Mead, G.P., Tang, L.X., Showell, P.J., Drayson, M.T. Drew, R. (2001) Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clinical Chemistry, 47, 673 680.
2. Cox, D.R. (1972) Regression models and life-tables. Journal of the Royal Statistical Society. Series B (Methodological), 34, 187 220.
3. Crespo, M., Bosch, F., Villamor, N., Bellosillo, B., Colomer, D., Rozman, M., Marce, S., Lopez-Guillermo, A., Campo, E. Montserrat, E. (2003) ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. New England Journal of Medicine, 348, 1764 1775.
4. Deegan, M.J., Abraham, J.P., Sawdyk, M. Van Slyck, E.J. (1984) High incidence of monoclonal proteins in the serum and urine of chronic lymphocytic leukemia patients. Blood, 64, 1207 1211.
5. Dingli, D., Kyle, R.A., Rajkumar, S.V., Nowakowski, G.S., Larson, D.R., Bida, J.P., Gertz, M.A., Therneau, T.M., Melton, III., L.J., Dispenzieri, A. Katzmann, J.A. (2006) Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood, 108, 1979 1983.
6. Dispenzieri, A., Lacy, M.Q., Katzmann, J.A., Rajkumar, S.V., Abraham, R.S., Hayman, S.R., Kumar, S.K., Clark, R., Kyle, R.A., Litzow, M.R., Inwards, D.J., Ansell, S.M., Micallef, I.M., Porrata, L.F., Elliott, M.A., Johnston, P.B., Greipp, P.R., Witzig, T.E., Zeldenrust, S.R., Russell, S.J., Gastineau, D. Gertz, M.A. (2006) Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood, 107, 3378 3383.
7. Dispenzieri, A., Kyle, R.A., Katzmann, J.A., Therneau, T.M., Larson, D., Benson, J., Clark, R.J., Melton, III., L.J., Gertz, M.A., Kumar, S.K., Fonseca, R., Jelinek, D.F. Rajlumar, S.V. (2008) Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood, 111, 785 789.
8. Drayson, M., Tang, L.X., Drew, R., Mead, G.P., Carr-Smith, H. Bradwell, A.R. (2001) Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood, 97, 2900 2902.
9. Drayson, M., Begum, G., Basu, S., Makkuni, S., Dunn, J., Barth, N. Child, J.A. (2006) Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood, 108, 2013 2019.
10. Itzykson, R., Le Garff-Tavernier, M., Katsahian, S., Diemert, M., Guis, L., Choquet, S., Musset, L. Leblond, V. (2006) Serum free light chain (SFLC) elevation is associated with high β2-microglobulin and with a shorter time to treatment in Waldenstroms macroglobulinemia. Blood, 108, 2419a.
11. Kaplan, E.L. Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457 481.
12. Katzmann, J.A., Abraham, R.S., Dispenzieri, A., Lust, J.A. Kyle, R.A. (2005) Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clinical Chemistry, 51, 878 881.
13. Kumar, S., Fonseca, R., Dispenzieri, A., Katzmann, J.A., Kyle, R.A., Clark, R. Rajkumar, S.V. (2006) High incidence of IgH translocations in monoclonal gammopathies with abnormal free light chain levels. Blood, 108, 3514a.
14. Kyrtsonis, M.C., Vassilakopoulos, T.P., Kafasi, N., Sachanas, S., Tzenou, T., Papadogiannis, A., Galanis, Z., Kalpadakis, C., Dimou, M., Kyriakou, E., Angelopoulou, M.K., Dimopoulou, M.N., Siakantaris, M.P., Dimitriadou, E.M., Kokoris, S.I., Panayiotidis, P. Pangalis, G.A. (2007) Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. British Journal Haematology, 137, 240 243.
15. Martin, W., Abraham, R., Shanafelt, T., Clark, R.J., Bone, N., Geyer, S.M., Katzmann, J.A., Bradwell, A., Kay, N.E. Witzig, T.E. (2007) Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Translational Research, 149, 231 235.
16. Matthews, C., Catherwood, M.A., Morris, T.C. Alexander, H.D. (2007) V(H)3-48 and V(H)3-53, as well as V(H)3-21, gene rearrangements define unique subgroups in CLL and are associated with biased lambda light chain restriction, homologous LCDR3 sequences and poor prognosis. Leukemia Research, 31, 231 234.
17. Moreau, A., Leleu, X., Manning, R., Coiteux, V., Darre, S., Hatjiharisi, E., Hunter, Z., Jia, X., Ngo, H., O'Sullivan, G., Santos, D., Treon, S., Facon, T., Anderson, K. Ghobial, I. (2006) Serum free light chain in Waldenstom Macroglobulinemia. Blood, 108, 2420a.
18. Oscier, D., Fegan, C., Hillmen, P., Illidge, T., Johnson, S., Maguire, P., Matutes, E. Milligan, D. (2004) Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. British Journal of Haematology, 125, 294 317.
19. Pascali, E. (1996) Monoclonal gammopathy and ctold agglutinin disease in non-Hodgkin's lymphoma. European Journal of Haematology, 56, 114 115.
20. Pascali, E. Pezzoli, A. (1986) Serum and urine monoclonal immunoglobulins in malignant non-Hodgkin's lymphoma. Acta Haematologica, 75, 193 198.
21. Perdigao, J., Cabrai, M.J., Costa, N., Carrao, C., Costa, P., Rodrigues, T. Raposo, J 2008) Prognostic factors in CLL: Is serum free light chain ratio a new biological marker? Annals of Oncology, 19 (suppl. 4 204. abstract 410.
22. Rajkumar, S.V., Kyle, R.A., Therneau, T.M., Melton, III., L.J., Bradwell, A.R., Clark, R.J., Larson, D.R., Plevak, M.F., Dispenzieri, A. Katzmann, J.A. (2005) Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood, 106, 812 817.
23. van Rhee, F., Bolejack, V., Hollmig, K., Pineda-Roman, M., Anaissie, E., Epstein, J., Shaughnessy, Jr., J.D., Zangari, M., Tricot, G., Mohiuddin, A., Alsayed, Y., Woods, G., Crowley, J. Barlogie, B. (2007) High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood, 110, 827 832.
24. Ruchlemer, R., Reinus, C., Paz, E., Cohen, A., Melnikov, N., Ronson, A. Rudensky, B. (2007) Free light chains, monoclonal proteins and chronic lymphocytic leukaemia. Blood, 110, 4697a.
25. Stankovic, T., Stewart, G.S., Fegan, C., Biggs, P., Last, J., Byrd, P.J., Keenan, R.D., Moss, P.A. Taylor, A.M. (2002) Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood, 99, 300 309.
26. λ2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood, 101, 4952 4957.